The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index.
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Open accessAbstract
Heat shock proteins (HSPs) are a large family of chaperones that are involved in protein folding and maturation of a variety of “client” proteins protecting them from degradation, oxidative stress, hypoxia, and thermal stress. Hence, they are significant regulators of cellular proliferation, differentiation and strongly implicated in the molecular orchestration of cancer development and progression as many of their clients are well established oncoproteins in multiple tumor types. Interestingly, tumor cells are more HSP chaperonage-dependent than normal cells for proliferation and survival because the oncoproteins in cancer cells are often misfolded and require augmented chaperonage activity for correction. This led to the development of several inhibitors of HSP90 and other HSPs that have shown promise both preclinically and clinically in the treatment of cancer. In this article, we comprehensively review the roles of some of the important HSPs in cancer, and how targeting them could be efficacious, especially when traditional cancer therapies fail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–266 of 266
HSP90 inhibitors in lung cancer: promise still unfulfilled.
Chatterjee, S., Bhattacharya, S., Socinski, M. A., & Burns, T. F. (2016) · PubMed · Cited by 60
Self-citationMortalin is a prognostic factor of gastric cancer with normal p53 function
Ando, K., Oki, E., Zhao, Y., Ikawa‐Yoshida, A., Kitao, H., Saeki, H., Kimura, Y., Ida, S., Morita, M., Kusumoto, T., et al. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0279-1 · Cited by 57
Heat shock proteins and cancer: How can nanomedicine be harnessed?
Sauvage, F., Messaoudi, S., Fattal, E., BARRATT, G. M., & Vergnaud, J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.013 · Cited by 57
Proteomic investigation of anti‐tumor activities exerted by sinularin against A 2058 melanoma cells
Su, T., Lin, J., Chiu, C., Chen, J. Y., Su, J., Cheng, Z., Hwang, W., Huang, H. H., & Wu, Y. (2012) · Electrophoresis · doi:10.1002/elps.201100462 · Cited by 56
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent
Hanson, B., & Vesole, D. H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903158934 · Cited by 56
Ullmann, R., Morbini, P., Halbwedl, I., Bongiovanni, M., Gogg-Kamerer, M., Papotti, M. G., Gabor, S., Renner, H., & Popper, H. (2004) · The Journal of Pathology · doi:10.1002/path.1584 · Cited by 56
Tid1 functions as a tumour suppressor in head and neck squamous cell carcinoma
Chen, C., Chiou, S., Huang, C., Jan, C., Lin, S., Hu, W., Chou, S., Liu, C., & Lo, J. (2009) · The Journal of Pathology · doi:10.1002/path.2604 · Cited by 55
Castle, P. E., Ashfaq, R., Ansari, F., & Muller, C. Y. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.045 · Cited by 53
DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis
Cui, X., Choi, H., Choi, Y.-S., Park, S., Sung, G., Lee, Y., Lee, J., Jun, W. J., Kim, K., Choi, K., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.041 · Cited by 52
The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60
Chaiwatanasirikul, K.-A., & Sala, A. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.99 · Cited by 51
Chen, C., Jan, C.-I., Lo, J., Yang, S.-C., Chang, Y., Pan, S., Wang, W.-L., Hong, T.-M., & Yang, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4066 · Cited by 51
Kimura, A., Ogata, K., Altan, B., Yokobori, T., Ide, M., Mochiki, E., Toyomasu, Y., Kogure, N., Yanoma, T., Suzuki, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7821 · Cited by 51
Wang, X., Sun, X., Chen, X., Facciponte, J. G., Repasky, E. A., Kane, J. M., & Subjeck, J. R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903891 · Cited by 50
Wang, X., & Subjeck, J. R. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.803607 · Cited by 50
Chatterjee, S., Huang, E. H. ‐., Christie, I., Kurland, B. F., & Burns, T. F. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0677 · Cited by 50
Self-citation3‘Sulfogalactolipid Binding Specifically Inhibits Hsp70 ATPase Activity in Vitro
Whetstone, H., & Lingwood, C. A. (2003) · Biochemistry · doi:10.1021/bi026735t · Cited by 49
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target
Zappasodi, R., Bongarzone, I., Ghedini, G. C., Castagnoli, L., Cabras, A. D., Messina, A., Tortoreto, M., Tripodo, C., Magni, M., Carlo‐Stella, C., et al. (2011) · Blood · doi:10.1182/blood-2011-06-364570 · Cited by 49
Targeting heat shock response pathways to treat pancreatic cancer
Xia, Y., Rocchi, P., Iovanna, J., & Peng, L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.016 · Cited by 49
Kim, S.-W., Hayashi, M., Lo, J., Fearns, C., Xiang, R., Lazennec, G., Yang, Y. C., & Lee, J.-D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4422 · Cited by 49
High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells
Tian, W., He, F., Fu, X., Lin, J., Tang, P., Huang, Y., Guo, R., & Sun, L. (2014) · Gene · doi:10.1016/j.gene.2014.03.046 · Cited by 48
Kasamatsu, A. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1178 · Cited by 48
Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function
Gibert, B., Simon, S., Dimitrova, V., Diaz‐Latoud, C., & Arrigo, A. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0075 · Cited by 48
Yamagishi, N., Ishihara, K., Saito, Y., & Hatayama, T. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.06.007 · Cited by 47
Expression of Heat Shock Protein (Hsp) 70 and Hsp 40 in Colorectal Cancer
Kanazawa, Y., Isomoto, H., Oka, M., Yano, Y., Soda, H., Shikuwa, S., Takeshima, F., Omagari, K., Mizuta, Y., Murase, K., et al. (2003) · Medical Oncology · doi:10.1385/mo:20:2:157 · Cited by 46
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
Ueno, T., Tsukuda, K., Toyooka, S., Ando, M., Takaoka, M., Soh, J., Asano, H., Maki, Y., Muraoka, T., Tanaka, N., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.09.011 · Cited by 46
Cheng, H., Cenciarelli, C., Nelkin, G. M., Tsan, R. Z., Fan, D., Cheng‐Mayer, C., & Fidler, I. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.25.1.44-59.2005 · Cited by 45
Hsp90 — a potential prognostic marker in CML
Žáčková, M., Moučková, D., Lopotová, T., Ondráčková, Z., Klamová, H., & Moravcová, J. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.11.002 · Cited by 44
Bae, M., Jeong, J., Kim, S., Kim, S. Y., Kang, H. J., Kim, D., Bae, S., Yun, I., Trentin, G. A., Rozakis-Adcock, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2735 · Cited by 44
Inhibiting Heat Shock Factor 1 in Human Cancer Cells with a Potent RNA Aptamer
Salamanca, H. H., Antonyak, M. A., Cerione, R. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096330 · Cited by 43
Targeting cancer with peptide aptamers
Seigneuric, R., Gobbo, J., Colas, P., & Garrido, C. (2011) · Oncotarget · doi:10.18632/oncotarget.297 · Cited by 42
Expression of heat shock proteins in medulloblastoma: Laboratory investigation
Alexiou, G. Α., Vartholomatos, G., Stefanaki, K. S., Patereli, A., Dova, L., Karamoutsios, A., Lallas, G., Sfakianos, G., Moschovi, M. A., & Prodromou, N. (2013) · Journal of Neurosurgery Pediatrics · doi:10.3171/2013.7.peds1376 · Cited by 39
Fu, W.-M., Zhang, J.-F., Wang, H., Xi, Z., Wang, W.-M., Zhuang, P., Zhu, X. M., Chen, S., Chan, T.-M., Leung, K., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.05.032 · Cited by 39
Yu, L., Yuan, X., Wang, D., Barakat, B., Williams, E. D., & Hannigan, G. E. (2013) · Oncogene · doi:10.1038/onc.2013.20 · Cited by 38
Kim, J. H., Kim, K.-J., Rhee, Y.-Y., Oh, S., Cho, N., Lee, H. S., & Kang, G. H. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.160 · Cited by 38
Huang, T.-Y., Chen, S., Han, H., Li, H., Huang, Z., Zhang, J., Yin, Q., Wang, X., Ma, X., Dai, P., et al. (2014) · Europe PMC (PubMed Central) · Cited by 37
Lentze, N., & Narberhaus, F. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.043 · Cited by 37
Yang, T., Li, X., Li, X.-G., Li, M., & Gao, P.-Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.011 · Cited by 35
Yerushalmi, R., Raiter, A., Nalbandyan, K., & Hardy, B. (2015) · Oncology Letters · doi:10.3892/ol.2015.3579 · Cited by 35
Patel, K. R., Wen, J., Magliocca, K. R., Müller, S., Liu, Y., Chen, Z. G., Saba, N. F., & Diaz, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2584-8 · Cited by 34
Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ
Cassel, J. A., Ilyin, S., McDonnell, M. E., & Reitz, A. B. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.067 · Cited by 34
Autoantibody to Heat Shock Protein Hsp40 in Sera of Lung Cancer Patients
Oka, M., Sato, S., Soda, H., Fukuda, M., Kawabata, S., Nakatomi, K., Shiozawa, K., Nakamura, Y., Ohtsuka, K., & Kohno, S. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb01097.x · Cited by 34
Suzuki, R., Hideshima, T., Mimura, N., Minami, J., Ohguchi, H., Kikuchi, S., Yoshida, Y., Görgün, G., Cirstea, D. D., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2014.300 · Cited by 33
Edwards, K. M., & Münger, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207732 · Cited by 33
Abu-hadid, M. M., Wilkes, J. D., El-Akawi, Z. J., Pendyala, L., & Perez, R. P. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00255-3 · Cited by 33
STRESS PROTEINS: NOMENCLATURE, DIVISION AND FUNCTIONS
Kopeček, P., Altmannová, K., & Weigl, E. (2001) · Biomedical Papers · doi:10.5507/bp.2001.010 · Cited by 33
Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3ε
Liffers, S.-T., Maghnouj, A., Munding, J. B., Jackstadt, R., Herbrand, U., Schulenborg, T., Marcus, K., Klein‐Scory, S., Schmiegel, W., Schwarte‐Waldhoff, I., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-137 · Cited by 33
Characterization of HSE sequences in human Hsp40 gene: structural and promoter analysis
Hata, M., & Ohtsuka, K. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(97)00208-x · Cited by 32
Kim, H. L., Sun, X., Subjeck, J. R., & Wang, X. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0258-z · Cited by 31
Stanhill, A., Levin, V., Hendel, A., Shachar, I., Kazanov, D., Arber, N., Kaminski, N., & Engelberg, D. (2005) · Oncogene · doi:10.1038/sj.onc.1209193 · Cited by 30
HSF1-Mediated Regulation of Tumor Cell Apoptosis: A Novel Target for Cancer Therapeutics
Kumar, S., Tomar, M. S., & Acharya, A. (2013) · Future Oncology · doi:10.2217/fon.13.106 · Cited by 29
Kurzik‐Dumke, U., Hörner, M., Czaja, J., Nicotra, M. R., Simiantonaki, N., Koslowski, M., & Natali, P. G. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.1.19 · Cited by 29
Immunoadjuvant chaperone, GRP170, induces ‘danger signals’ upon interaction with dendritic cells
Manjili, M. H., Park, J., Facciponte, J. G., Wang, X., & Subjeck, J. R. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01418.x · Cited by 28
Abdalla, M. A. K., & Haj-Ahmad, Y. (2012) · Journal of Cancer · doi:10.7150/jca.4280 · Cited by 28
Ren, F., Xu, Y., Mao, L., Ou, R., Ding, Z., Zhang, X., Tang, J., Li, B., Jia, Z., Tian, Z., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.2.10391 · Cited by 27
Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer
Zhang, S., Hu, Y., Huang, Y.-W., Xu, H., Wu, G., & Dai, H. (2015) · Oncology Letters · doi:10.3892/ol.2015.3073 · Cited by 26
Lee, Y., Sunada, S., Hirakawa, H., Fujimori, A., Nickoloff, J. A., & Okayasu, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0573 · Cited by 26
Jang, W., Jung, S., Kang, J. S., Jeong, J., Bae, M., Joo, S. H., Park, G. H., Kundu, J. K., Hong, Y., & Jeong, C. (2014) · Cancer Science · doi:10.1111/cas.12497 · Cited by 25
HSP60 interacts with YB-1 and affects its polysome association and subcellular localization
Ohashi, S., Atsumi, M., & Kobayashi, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.094 · Cited by 23
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
Gomez-Casal, R., Bhattacharya, C., Epperly, M. W., Basse, P. H., Wang, H., Wang, X., Proia, D. A., Greenberger, J. S., Socinski, M. A., & Levina, V. V. (2015) · Cancers · doi:10.3390/cancers7020814 · Cited by 22
Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
Castagnola, P., Bellese, G., Birocchi, F., Gagliani, M. C., Tacchetti, C., & Cortese, K. (2016) · Oncotarget · doi:10.18632/oncotarget.13392 · Cited by 20
Cai, M.-B., Wang, X.-P., Zhang, J., Han, H.-Q., Liu, C.-C., Bei, J., Peng, R.-J., Liang, Y., Feng, Q.-S., Wang, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-96 · Cited by 19
Chatterjee, S., Huang, E. H. ‐., Christie, I., & Burns, T. F. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0114 · Cited by 18
Self-citationYokomine, K., Nakatsura, T., Senju, S., Nakagata, N., Minohara, M., Kira, J., Motomura, Y., Kubo, T., Sasaki, Y., & Nishimura, Y. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00612.x · Cited by 17
Nagata, Y., Kudo, M., Nagai, T., Watanabe, T., Kawasaki, M., Asakuma, Y., Hagiwara, S., Nishida, N., Matsui, S., Kashida, H., et al. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2342-x · Cited by 12
Designing Drugs Against Hsp90 for Cancer Therapy
Ochiana, S. O., Taldone, T., & Chiosis, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1130-1_7 · Cited by 11
Castro, G. N., Cayado-Gutiérrez, N., Moncalero, V. L., Lima, P., Angelis, R. L. D., Chávez, V., Cuello-Carrión, F. D., & Ciocca, D. R. (2012) · Cell Stress and Chaperones · doi:10.1007/s12192-012-0350-6 · Cited by 10
Cited by
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
Hu, C., Yang, J., Qi, Z., Wu, H., Wang, B., Zou, F., Mei, H., Liu, J., Wang, W., & Liu, Q. (2022) · MedComm · doi:10.1002/mco2.161 · Cited by 779
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Hoter, A., El-Sabban, M. E., & Naim, H. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092560 · Cited by 693
Chen, X., Zhao, Y., Luo, W., Chen, S., Lin, F., Zhang, X., Fan, S., Shen, X., Wang, Y., & Liang, G. (2020) · Theranostics · doi:10.7150/thno.46728 · Cited by 291
Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy
Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019) · Cells · doi:10.3390/cells9010060 · Cited by 284
Crucial players in glycolysis: Cancer progress
Abbaszadeh, Z., Çeşmeli, S., & Biray Avcı, Ç. (2020) · Gene · doi:10.1016/j.gene.2019.144158 · Cited by 274
Metadata
- Authors
- Chatterjee, S., & Burns, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-09-15
- Volume
- 18
- Issue
- 9
- Pages
- 1978
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2755428803
- Cited by
- 501
- References
- 266
- FWCI
- 19.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.